NCT00686751 - Immune Effects of Vitamin D in Hemodialysis Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

End Stage Renal DiseaseHemodialysisInflammatory ResponseCardiovascular Disease

Interventions

DRUG

paricalcitol

Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.

Trial Locations (3)

10003

Irving Place Dialysis Center, New York

10025

Upper Manhattan Dialysis Center, New York

10128

Yorkville Dialysis Center, New York